• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Myomo Reports Record Third Quarter Financial and Operating Results

    11/6/24 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care
    Get the next $MYO alert in real time by email

    $9.2 million in revenue, raises full-year revenue guidance

    225 MyoPro® authorizations and orders with 316 patients in backlog at quarter end

    645 additions to the pipeline result in 1,263 patients in the pipeline as of September 30, 2024

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2024.

    Financial and operating highlights for the third quarter of 2024 include the following (all comparisons are with the third quarter of 2023 unless otherwise indicated):

    • Product and total revenue was a record $9.2 million, up 83% and 81%, respectively;
    • Revenue units were a record 161, up 35%;
    • Orders and insurance authorizations were received for a record 225 MyoPro units, up 44%;
    • Backlog, which represents insurance authorizations and orders received but not yet converted to revenue, was a record 316 units as of September 30, 2024, up 71%;
    • A record 645 new candidates were added to the patient pipeline, up 69%;
    • There were 1,263 MyoPro candidates in the patient pipeline as of September 30, 2024, up 21%;
    • Gross margin was 75.4%, up 670 basis points, with gross margin on product revenues up 700 basis points;
    • Cost per pipeline add was $1,618, down 25%; and
    • The Company launched its orthotics and prosthetics ("O&P") channel program at the American Orthotic and Prosthetic Association (AOPA) National Assembly in September, and began training O&P clinics to provide the MyoPro to their patients.

    Management Commentary

    "Myomo delivered a second consecutive quarter of record financial and operating results as we emphasized outreach and education to the Medicare population regarding the benefits of the MyoPro, as well as an unwavering commitment to efficiency, quality and improving patient outcomes across our organization", said Paul R. Gudonis, Myomo's chairman and chief executive officer. "Our focus has been on accelerating revenue growth though our direct provider sales channel and laying the groundwork for growth in the O&P channel in 2025 and beyond. Demonstrable progress was made on both of these areas during the third quarter."

    Financial Results

     

    For the Three Months

    Ended September 30,

     

    Period-

    to-Period

    Change

     

    For the Nine Months

    Ended September 30,

     

    Period-

    to-Period

    Change

     

     

    2024

     

    2023

     

    $

     

    %

     

    2024

     

    2023

     

    $

     

    %

     

    Product revenue

    $

    9,207,586

     

    $

    5,029,523

     

    $

    4,178,063

     

     

    83

    %

    $

    20,482,742

     

    $

    12,719,855

     

    $

    7,762,887

     

     

    61

    %

    License revenue

     

    —

     

     

    50,000

     

     

    (50,000

    )

     

    (100

    )%

     

    —

     

     

    1,764,920

     

     

    (1,764,920

    )

     

    (100

    )%

    Total revenue

     

    9,207,586

     

     

    5,079,523

     

     

    4,128,063

     

     

    81

    %

     

    20,482,742

     

     

    14,484,775

     

     

    5,997,967

     

     

    41

    %

    Cost of revenue

     

    2,262,031

     

     

    1,590,675

     

     

    671,356

     

     

    42

    %

     

    5,912,632

     

     

    4,407,270

     

     

    1,505,362

     

     

    34

    %

    Gross profit

    $

    6,945,555

     

    $

    3,488,848

     

    $

    3,456,707

     

     

    99

    %

    $

    14,570,110

     

    $

    10,077,505

     

    $

    4,492,605

     

     

    45

    %

    Gross margin %

     

    75.4

    %

     

    68.7

    %

     

     

     

    6.7

    %

     

    71.1

    %

     

    69.6

    %

     

     

     

    1.5

    %

    Revenue for the third quarter of 2024 was $9.2 million, up 81% compared with the third quarter of 2023. Product revenue increased 83% compared with the same period a year ago, driven by growth in revenue units and by a higher average selling price ("ASP"). Myomo recognized revenue on 161 MyoPro units in the third quarter of 2024, up 35% over the same quarter a year ago. ASP was approximately $57,200 in the third quarter, up 35%. A portion of the increase in ASP reflects payments from supplemental insurance payers on revenue units recognized in a prior period. Excluding these payments, ASP was approximately $52,700, up 23%. Effective July 1, 2024, revenue for Medicare Part B patients is being recognized at the time of product delivery for the amount expected to be paid for each patient. Revenue from patients with Medicare Part B represented 55% of revenue in the third quarter. Year-to-date revenue was $20.5 million, up 41% compared with the same period a year ago. Year-to-date product revenue was up 61% compared with the first nine months of 2023.

    Gross margin for the third quarter of 2024 was 75.4%, compared with 68.7% for the third quarter of 2023. The increase was driven primarily by a higher ASP. Gross margin on product revenues for the third quarter of 2023 was 68.4%. Year-to-date gross margin was 71.1% compared with 69.6% for the same period a year ago. Gross margin on product revenue for the first nine months of 2023 was 65.4%.

    Operating expenses for the third quarter of 2024 were $7.9 million, an increase of 43% compared with the third quarter of 2023. The increase was driven primarily by higher payroll expense due to additional headcount to support the Company's engineering efforts, as well as the addition of field clinical and reimbursement capacity and incentive compensation accruals. Advertising costs of $1.0 million were up 23% over the third quarter of 2023. Cost per pipeline add was $1,618, a decrease of 25% compared with the third quarter of 2023. Year-to-date operating expenses were $20.5 million, an increase of 29% compared with the same period a year ago.

    Operating loss for the third quarter of 2024 was $1.0 million, compared with $2.0 million for the third quarter of 2023. Net loss for the third quarter of 2024 was $1.0 million, or $0.03 per share, compared with a net loss of $2.0 million, or $0.06 per share, for the third quarter of 2023. Year-to-date operating loss was $6.0 million, compared with an operating loss of $5.8 million for the same period a year ago. Year-to-date net loss was $5.9 million, or $0.16 per share, compared with a net loss of $5.7 million, or $0.21 per share, for the same period a year ago.

    Adjusted EBITDA for the third quarter of 2024 was $(0.6) million, compared with $(1.7) million for the third quarter of 2023. Year-to-date Adjusted EBITDA was $(5.3) million, compared with $(4.9) million for the same period a year ago. A reconciliation of GAAP net loss to this non-GAAP financial measure appears below.

    Operations Update

    The patient pipeline was 1,263 patients as of September 30, 2024, compared with 1,046 as of September 30, 2023, an increase of 21%. A record 645 patients were added to the pipeline during the third quarter of 2024, an increase of 69% compared with the same period a year ago. The Company generated a record 225 authorizations and orders in the third quarter of 2024, an increase of 44% compared with the same period a year ago. As a result, backlog was a record 316 patients as of September 30, 2024, an increase of 71% compared with September 30, 2023.

    Cash Position

    Cash, cash equivalents and restricted cash as of September 30, 2024 were $7.0 million. Cash used in operating activities was $1.5 million for the third quarter of 2024, compared with $1.7 million for the third quarter of 2023. Cash used in operating activities in the third quarter of 2024 was impacted by a payment delay during the last two to three weeks of the quarter from the Centers for Medicare & Medicaid Services ("CMS") due to a transition from check payments to electronic funds transfer, which is expected to speed up payments going forward. The delayed payments were subsequently received in October.

    Business Outlook

    "We are positioned to deliver sequential revenue growth in the fourth quarter due to the strength of our backlog," added Mr. Gudonis. "As a result, we expect fourth quarter revenue to be in the range of $9.5 million to $10.5 million, resulting in full year revenue of $30 million to $31 million, up from our previous guidance of $28 million to $30 million."

    "We believe our objective of reaching operating cash flow breakeven in the fourth quarter is achievable. We also expect to approach Adjusted EBITDA breakeven in the fourth quarter. We expect a moderation in cash used to fund growth in working capital, as we collected in the fourth quarter the Medicare payments that were delayed from the third quarter," said David Henry, Myomo's chief financial officer. "Moderation in the growth of working capital in the fourth quarter is predicated on minimizing growth in days sales outstanding and receipt of a contractual reimbursement from the landlord for initial costs associated with the lease on our new facility."

    Conference Call and Webcast

    Myomo will hold a conference call today at 4:30 p.m. Eastern time to discuss these results and answer questions. Participants are encouraged to pre-register for the call at this link. Callers who pre-register will receive a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time up to and after the start of the call. Those unable to pre-register may participate by dialing 844-707-6932 (U.S.) or 412-317-9250 (International). A webcast of the call will also be available at Myomo's Investor Relations page at http://ir.myomo.com/.

    A replay of the webcast will be available beginning approximately one hour after the completion of the live conference call at http://ir.myomo.com/. A dial-in replay of the call will be available until November 20, 2024 at 877-344-7529 (U.S. toll-free), 855-669-9658 (Canada toll-free) or 412-317-0088 (International), with passcode 3377340.

    Non-GAAP Financial Measures

    Myomo is providing financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. This information includes Adjusted EBITDA. This non-GAAP financial measure is not in accordance with, or an alternative for, GAAP and may be different from similar non-GAAP financial measures used by other companies. Myomo believes the use of this non-GAAP financial measure provides supplementary information for investors to use in evaluating operating performance and in comparing Myomo's financial measures with other companies in its industry, many of which present similar non-GAAP financial measures. Adjusted EBITDA is EBITDA adjusted for stock-based compensation expense and loss on equity investment. This non-GAAP financial measure is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP, and should be viewed in conjunction with GAAP financial measures. Investors are encouraged to review the reconciliation of this non-GAAP measure to its most directly comparable GAAP financial measure. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables included as part of this press release.

    About Myomo

    Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

    Forward-Looking Statements

    This press release contains forward-looking statements regarding the Company's future business expectations, including expectations for fourth quarter and full year 2024 revenue, as well as expectations regarding achieving operating cash flow breakeven and approaching Adjusted EBITDA breakeven in the fourth quarter of 2024, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

    These factors include, among other things:

    • our ability to obtain sufficient reimbursement from third-party payers for our products;
    • our ability to navigate factors both within and outside our control to grow revenues sufficiently to achieve operating cash flow breakeven on a quarterly basis;
    • our revenue concentration with Medicare and with a particular insurance payer as a result of focusing our efforts on patients with insurers who have previously reimbursed for the MyoPro;
    • our ability to continue normal operations and patient interactions without supply chain disruption in order to deliver and fit our custom-fabricated devices;
    • our marketing and commercialization efforts;
    • our dependence upon external sources for the financing of our operations, to the extent that we do not achieve or maintain cash flow breakeven;
    • our ability to obtain and maintain our strategic collaborations and to realize the intended results of such collaborations;
    • our ability to effectively execute our business plan and scale up our operations;
    • our expectations as to our product development programs, including improving our existing products and developing new products;
    • our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our products;
    • our expectations as to our clinical research program and clinical results;
    • our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others;
    • our ability to gain and maintain regulatory approvals;
    • our ability to compete and succeed in a highly competitive and evolving industry; and
    • general market, economic, environmental and social factors that may affect the evaluation, fitting, delivery and sale of our products to patients.

    More information about these and other factors that potentially could affect our financial results is included in Myomo's filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material or adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

     

    MYOMO, INC.

     CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

     

     

     

    For the Three Months ended

     

     

    For the Nine Months Ended

     

     

     

    September 30,

     

     

    September 30,

     

     

     

    2024

     

     

    2023

     

     

    2024

     

     

    2023

     

    Revenue

     

     

     

     

     

     

     

     

     

     

     

     

    Product revenue

     

    $

    9,207,586

     

     

    $

    5,029,523

     

     

    $

    20,482,742

     

     

    $

    12,719,855

     

    License revenue

     

     

    —

     

     

     

    50,000

     

     

     

    —

     

     

     

    1,764,920

     

     

     

     

    9,207,586

     

     

     

    5,079,523

     

     

     

    20,482,742

     

     

     

    14,484,775

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Cost of revenue

     

     

    2,262,031

     

     

     

    1,590,675

     

     

     

    5,912,632

     

     

     

    4,407,270

     

    Gross profit

     

     

    6,945,555

     

     

     

    3,488,848

     

     

     

    14,570,110

     

     

     

    10,077,505

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

     

    Research and development

     

     

    1,248,870

     

     

     

    717,256

     

     

     

    3,212,309

     

     

     

    1,758,480

     

    Selling, clinical and marketing

     

     

    3,401,182

     

     

     

    2,387,090

     

     

     

    8,540,161

     

     

     

    6,689,578

     

    General and administrative

     

     

    3,253,056

     

     

     

    2,408,871

     

     

     

    8,779,024

     

     

     

    7,427,818

     

     

     

     

    7,903,108

     

     

     

    5,513,217

     

     

     

    20,531,494

     

     

     

    15,875,876

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Loss from operations

     

     

    (957,553

    )

     

     

    (2,024,369

    )

     

     

    (5,961,384

    )

     

     

    (5,798,371

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

    Other (income) expense, net

     

     

     

     

     

     

     

     

     

     

     

     

    Interest income, net

     

     

    (76,020

    )

     

     

    (112,300

    )

     

     

    (318,555

    )

     

     

    (302,053

    )

    Other expense, net

     

     

    —

     

     

     

    467

     

     

     

    —

     

     

     

    6,098

     

    Loss on equity investment

     

     

    —

     

     

     

    70,124

     

     

     

    —

     

     

     

    99,840

     

     

     

     

    (76,020

    )

     

     

    (41,709

    )

     

     

    (318,555

    )

     

     

    (196,115

    )

    Loss before income taxes

     

     

    (881,533

    )

     

     

    (1,982,660

    )

     

     

    (5,642,829

    )

     

     

    (5,602,256

    )

    Income tax expense

     

     

    84,876

     

     

     

    46,356

     

     

     

    280,819

     

     

     

    85,204

     

    Net loss

     

    $

    (966,409

    )

     

    $

    (2,029,016

    )

     

    $

    (5,923,648

    )

     

    $

    (5,687,461

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted average number of common shares outstanding:

     

     

     

     

     

     

     

     

     

     

     

     

    Basic and diluted

     

     

    37,950,515

     

     

     

    35,266,361

     

     

     

    37,359,366

     

     

     

    27,537,357

     

    Net loss per share attributable to common stockholders

     

     

     

     

     

     

     

     

     

     

     

     

    Basic and diluted

     

    $

    (0.03

    )

     

    $

    (0.06

    )

     

    $

    (0.16

    )

     

    $

    (0.21

    )

     

     

    MYOMO, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

     

     

     

    September 30,

     

     

    December 31,

     

     

     

    2024

     

     

    2023

     

     

     

    (unaudited)

     

     

     

     

    ASSETS

     

     

     

     

     

     

    Current Assets:

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    6,622,675

     

     

    $

    6,871,306

     

    Short-term investments

     

     

    —

     

     

     

    1,994,662

     

    Accounts receivable, net

     

     

    3,729,387

     

     

     

    2,382,658

     

    Inventories, net

     

     

    3,383,513

     

     

     

    1,803,507

     

    Prepaid expenses and other current assets

     

     

    968,569

     

     

     

    598,850

     

    Total Current Assets

     

     

    14,704,144

     

     

     

    13,650,983

     

    Restricted cash

     

     

    375,000

     

     

     

    —

     

    Operating lease assets with right of use

     

     

    466,962

     

     

     

    663,554

     

    Equipment, net

     

     

    561,325

     

     

     

    175,794

     

    Other assets

     

     

    205,440

     

     

     

    91,237

     

    Total Assets

     

    $

    16,312,871

     

     

    $

    14,581,568

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

     

     

    Current Liabilities:

     

     

     

     

     

     

    Accounts payable and accrued expenses

     

     

    6,448,076

     

     

     

    4,885,944

     

    Current operating lease liability

     

     

    205,464

     

     

     

    486,143

     

    Income taxes payable

     

     

    305,861

     

     

     

    96,461

     

    Deferred revenue

     

     

    31,971

     

     

     

    8,510

     

    Total Current Liabilities

     

     

    6,991,372

     

     

     

    5,477,058

     

    Non-current operating lease liability

     

     

    29,165

     

     

     

    115,160

     

    Total Liabilities

     

     

    7,020,537

     

     

     

    5,592,218

     

    Commitments and Contingencies

     

     

    —

     

     

     

    —

     

    Stockholders' Equity:

     

     

     

     

     

     

    Preferred stock

     

     

    —

     

     

     

    —

     

    Common stock

     

     

    3,026

     

     

     

    2,715

     

    Additional paid-in capital

     

     

    111,754,495

     

     

     

    105,840,239

     

    Accumulated other comprehensive income

     

     

    395,734

     

     

     

    83,669

     

    Accumulated deficit

     

     

    (102,854,457

    )

     

     

    (96,930,809

    )

    Treasury stock, at cost

     

     

    (6,464

    )

     

     

    (6,464

    )

    Total Stockholders' Equity

     

     

    9,292,334

     

     

     

    8,989,350

     

    Total Liabilities and Stockholders' Equity

     

    $

    16,312,871

     

     

    $

    14,581,568

     

     

    MYOMO, INC.

     CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

     

    For the Nine Months Ended September 30,

     

    2024

     

     

    2023

     

    CASH FLOWS FROM OPERATING ACTIVITIES

     

     

     

     

     

     

    Net loss

     

    $

    (5,923,648

    )

     

    $

    (5,687,461

    )

    Adjustments to reconcile net loss to net cash used in operations:

     

     

     

     

     

     

    Depreciation

     

     

    114,346

     

     

     

    136,416

     

    Stock-based compensation

     

     

    552,580

     

     

     

    781,513

     

    Accretion of discount on short-term investments

     

     

    (108,999

    )

     

     

    —

     

    Credit losses

     

     

    5,257

     

     

     

    12,626

     

    Loss on equity investment

     

     

    —

     

     

     

    99,840

     

    Amortization of right-of-use assets

     

     

    196,592

     

     

     

    301,053

     

    Other non-cash charges

     

     

    84,180

     

     

     

    (49,271

    )

    Changes in operating assets and liabilities:

     

     

     

     

     

     

    Accounts receivable

     

     

    (1,116,352

    )

     

     

    (625,596

    )

    Inventories

     

     

    (1,573,193

    )

     

     

    (90,100

    )

    Prepaid expenses and other current assets

     

     

    (614,951

    )

     

     

    (439,584

    )

    Other assets

     

     

    (16,640

    )

     

     

    19,797

     

    Accounts payable and accrued expenses

     

     

    1,895,795

     

     

     

    2,141,978

     

    Income taxes payable

     

     

    202,137

     

     

     

    (74,944

    )

    Operating lease liabilities

     

     

    (366,675

    )

     

     

    (352,820

    )

    Deferred revenue

     

     

    23,460

     

     

     

    9,533

     

    Net cash used in operating activities

     

     

    (6,655,632

    )

     

     

    (3,817,020

    )

    CASH USED IN INVESTING ACTIVITIES

     

     

    1,613,180

     

     

     

    (4,324,017

    )

    CASH PROVIDED BY FINANCING ACTIVITIES

     

     

    5,162,409

     

     

     

    9,713,426

     

    Effect of foreign exchange rate changes on cash

     

     

    6,412

     

     

     

    (6,610

    )

     

     

     

     

     

     

     

    'Net (decrease) increase in cash and cash equivalents and restricted cash

     

     

    126,369

     

     

     

    1,565,780

     

     

     

     

     

     

     

     

    Cash, cash equivalents and restricted cash, beginning of period

     

     

    6,871,306

     

     

     

    5,345,967

     

     

     

     

     

     

     

     

    Cash, cash equivalents and restricted cash, end of period

     

    $

    6,997,675

     

     

    $

    6,911,747

     

     

     

    MYOMO, INC.

    RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

    (unaudited)

     

     

     

    For the Three Months

    Ended September 30,

     

     

    For the Nine Months

    Ended September 30,

     

     

     

    2024

     

     

    2023

     

     

    2024

     

     

    2023

     

    GAAP net loss

     

    $

    (966,409

    )

     

    $

    (2,029,016

    )

     

    $

    (5,923,648

    )

     

    $

    (5,687,461

    )

    Adjustments to reconcile to Adjusted EBITDA:

     

     

     

     

     

     

     

     

     

     

     

     

    Interest income

     

     

    (76,020

    )

     

     

    (112,300

    )

     

     

    (318,555

    )

     

     

    (302,053

    )

    Depreciation expense

     

     

    48,682

     

     

     

    35,794

     

     

     

    114,346

     

     

     

    136,416

     

    Stock-based compensation

     

     

    324,185

     

     

     

    330,394

     

     

     

    552,580

     

     

     

    781,513

     

    Loss on investment in minority interest

     

     

    —

     

     

     

    70,124

     

     

     

    —

     

     

     

    99,840

     

    Income tax expense

     

     

    84,876

     

     

     

    46,356

     

     

     

    280,819

     

     

     

    85,204

     

    Adjusted EBITDA

     

    $

    (584,686

    )

     

    $

    (1,658,648

    )

     

    $

    (5,294,458

    )

     

    $

    (4,886,541

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241106431006/en/

    Get the next $MYO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MYO

    DatePrice TargetRatingAnalyst
    7/31/2024$7.00Buy
    Craig Hallum
    5/20/2024$7.00Buy
    Lake Street
    12/15/2023$6.50Buy
    H.C. Wainwright
    More analyst ratings

    $MYO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Myomo Inc.

      10-Q - MYOMO, INC. (0001369290) (Filer)

      5/7/25 4:15:23 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MYOMO, INC. (0001369290) (Filer)

      5/7/25 4:10:10 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • SEC Form DEFA14A filed by Myomo Inc.

      DEFA14A - MYOMO, INC. (0001369290) (Filer)

      4/25/25 8:35:25 AM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kirk Thomas F bought $37,000 worth of shares (7,400 units at $5.00), increasing direct ownership by 3% to 255,933 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      3/14/25 9:00:08 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Kirk Thomas F bought $175,000 worth of shares (50,000 units at $3.50), increasing direct ownership by 27% to 236,499 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      5/31/24 5:43:26 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Kirk Thomas F bought $175,000 worth of shares (50,000 units at $3.50), increasing direct ownership by 37% to 186,499 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      3/18/24 7:48:52 AM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Financials

    Live finance-specific insights

    See more
    • Myomo Reports First Quarter 2025 Financial and Operating Results

      Revenue of $9.8 million Record 700 patients added to the pipeline More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025. Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated): Revenue was $9.8 million, up 162%; Revenu

      5/7/25 5:11:00 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo to Report First Quarter 2025 Financial Results on May 7

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2025 on May 7, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the cal

      4/30/25 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million

      Generated first-ever positive quarterly cash flow from operations Received a record 233 MyoPro® authorizations and orders with 657 additions to the pipeline Introduces 2025 revenue guidance of $50 million to $53 million Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2024. Financial and operating highlights for the fourth quarter of 2024 include the following (all comparisons are with the fourth quarter of

      3/10/25 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Myomo Reports First Quarter 2025 Financial and Operating Results

      Revenue of $9.8 million Record 700 patients added to the pipeline More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025. Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated): Revenue was $9.8 million, up 162%; Revenu

      5/7/25 5:11:00 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo to Host Investor & Analyst Day Event on June 18, 2025

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces the Company will be hosting its first-ever Investor & Analyst Day event on Wednesday, June 18, 2025. The event will take place at Myomo's new corporate headquarters and manufacturing facility in Burlington, Mass., and will offer an in-depth look at the Company's latest innovations, strategic plans and growth initiatives to empower individuals with neuromuscular disorders through cutting-edge wearable medical robotics. Institutional investors, shareholders and analysts are invited to reg

      5/1/25 8:30:00 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo to Report First Quarter 2025 Financial Results on May 7

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2025 on May 7, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the cal

      4/30/25 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Leadership Updates

    Live Leadership Updates

    See more
    • Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

      2/3/25 4:00:00 PM ET
      $INGN
      $MDT
      $MYO
      Industrial Specialties
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Myomo Appoints Heather Getz to its Board of Directors

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin

      3/28/24 4:05:00 PM ET
      $BFLY
      $MYO
      Medical Electronics
      Health Care
      Industrial Specialties
    • Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Jacobovitz, 47, is currently a partner and lead healthcare analyst at AIGH Capital Management and affiliates ("AIGH"), where he has significantly grown AIGH's healthcare footprint since joining in 2014. Prior to AIGH, Mr. Jacobovitz was a managing director at Capstone, a policy research

      1/30/23 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Myomo with a new price target

      Craig Hallum initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

      7/31/24 7:20:07 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Lake Street initiated coverage on Myomo with a new price target

      Lake Street initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

      5/20/24 9:00:38 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • H.C. Wainwright initiated coverage on Myomo with a new price target

      H.C. Wainwright initiated coverage of Myomo with a rating of Buy and set a new price target of $6.50

      12/15/23 8:26:14 AM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Myomo Inc.

      SC 13G/A - MYOMO, INC. (0001369290) (Subject)

      10/18/24 2:21:35 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Myomo Inc.

      SC 13G/A - MYOMO, INC. (0001369290) (Subject)

      7/12/24 10:35:49 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Myomo Inc.

      SC 13G/A - MYOMO, INC. (0001369290) (Subject)

      7/11/24 6:02:07 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Commercial Officer Mitchell Micah sold $247,565 worth of shares (48,000 units at $5.16), decreasing direct ownership by 25% to 140,269 units (SEC Form 4)

      4/A - MYOMO, INC. (0001369290) (Issuer)

      3/21/25 4:15:53 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Director Kirk Thomas F bought $37,000 worth of shares (7,400 units at $5.00), increasing direct ownership by 3% to 255,933 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      3/14/25 9:00:08 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Amendment: Chief Commercial Officer Mitchell Micah sold $247,565 worth of shares (48,000 units at $5.16), decreasing direct ownership by 25% to 140,572 units (SEC Form 4)

      4/A - MYOMO, INC. (0001369290) (Issuer)

      3/14/25 5:45:37 PM ET
      $MYO
      Industrial Specialties
      Health Care